The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients.

BACKGROUND AND OBJECTIVES While it has long been recognized that patients with acute unprovoked deep vein thrombosis (DVT) or pulmonary embolism (PE) have a higher risk of recurrent venous thromboembolism (VTE) than that of patients with secondary thrombosis, whether other clinical parameters can help predict the development of recurrent events is controversial. The aim of this investigation was to assess the rate of recurrent VTE after withdrawal of vitamin K antagonists, and to identify clinical parameters associated with a higher likelihood of recurrence. DESIGN AND METHODS We followed, up to a maximum of 10 years, 1626 consecutive patients who had discontinued anticoagulation after a first episode of clinically symptomatic proximal DVT and/or PE. All patients with clinically suspected recurrent VTE underwent objective tests to confirm or rule out the clinical suspicion. RESULTS After a median follow-up of 50 months, 373 patients (22.9%) had had recurrent episodes of VTE. The cumulative incidence of recurrent VTE was 11.0% (95% CI, 9.5-12.5) after 1 year, 19.6% (17.5-21.7) after 3 years, 29.1% (26.3-31.9) after 5 years, and 39.9% (35.4-44.4) after 10 years. The adjusted hazard ratio for recurrent VTE was 2.30 (95% CI, 1.82-2.90) in patients whose first VTE was unprovoked, 2.02 (1.52-2.69) in those with thrombophilia, 1.44 (1.03-2.03) in those presenting with primary DVT, 1.39 (1.08-1.80) for patients who received a shorter (up to 6 months) duration of anticoagulation, and 1.14 (1.06-1.12) for every 10-year increase of age. When the analysis was confined to patients with unprovoked VTE the results did not change. INTERPRETATION AND CONCLUSIONS Besides unprovoked presentation, other factors independently associated with a statistically significant increased risk of recurrent VTE are thrombophilia, clinical presentation with primary DVT, shorter duration of anticoagulation, and increasing age.

[1]  S. Schulman,et al.  Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis , 2006, The Lancet.

[2]  Bradley Flansbaum,et al.  Clinical factors and recurrent venous thrombotic events. , 2005, JAMA.

[3]  D. Ost,et al.  Duration of anticoagulation following venous thromboembolism: a meta-analysis. , 2005, JAMA.

[4]  Frits R Rosendaal,et al.  Thrombophilia, clinical factors, and recurrent venous thrombotic events. , 2005, JAMA.

[5]  T. Baglin,et al.  High risk of recurrent venous thromboembolism in men , 2004, Journal of thrombosis and haemostasis : JTH.

[6]  E. Minar,et al.  The risk of recurrent venous thromboembolism in men and women. , 2004, The New England journal of medicine.

[7]  E. Minar,et al.  Symptomatic pulmonary embolism and the risk of recurrent venous thromboembolism , 2004 .

[8]  T. Baglin,et al.  Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study , 2003, The Lancet.

[9]  F. Bernardi,et al.  Predictive Value of D‐Dimer Test for Recurrent Venous Thromboembolism After Anticoagulation Withdrawal in Subjects With a Previous Idiopathic Event and in Carriers of Congenital Thrombophilia , 2003, Circulation.

[10]  W. Ageno,et al.  Extended Oral Anticoagulant Therapy after a First Episode of Pulmonary Embolism , 2003, Annals of Internal Medicine.

[11]  P. Grenier,et al.  Diagnostic strategy for patients with suspected pulmonary embolism: a prospective multicentre outcome study , 2002, The Lancet.

[12]  P. Prandoni,et al.  The Diagnostic Value of Compression Ultrasonography in Patients with Suspected Recurrent Deep Vein Thrombosis , 2002, Thrombosis and Haemostasis.

[13]  P. Prandoni,et al.  Three months vs. one year of oral anticoagulant therapy for idiopathic deep venous thrombosis , 2002 .

[14]  W. Ageno,et al.  Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. , 2001, The New England journal of medicine.

[15]  I. Durieu,et al.  Comparison of 3 and 6 Months of Oral Anticoagulant Therapy After a First Episode of Proximal Deep Vein Thrombosis or Pulmonary Embolism and Comparison of 6 and 12 Weeks of Therapy After Isolated Calf Deep Vein Thrombosis , 2001, Circulation.

[16]  P. Ridker,et al.  G20210A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism. , 2001, Journal of the American College of Cardiology.

[17]  Comparison of long versus short duration of anticoagulant therapy after a first episode of venous thromboembolism: a meta‐analysis of randomized, controlled trials , 2000, Journal of internal medicine.

[18]  H. Eriksson,et al.  Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. , 2000, Archives of internal medicine.

[19]  M. Prins,et al.  Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutationRisk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis , 2000 .

[20]  L. Melton,et al.  Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. , 2000, Archives of internal medicine.

[21]  M. Margaglione,et al.  Coexistence of Factor V Leiden and Factor II A20210 Mutations and Recurrent Venous Thromboembolism , 1999, Thrombosis and Haemostasis.

[22]  G Leone,et al.  The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. , 1999, The New England journal of medicine.

[23]  P. Simioni.  The molecular genetics of familial venous thrombosis. , 1999, Bailliere's best practice & research. Clinical haematology.

[24]  B. Wiman,et al.  The Risk of Recurrent Venous Thromboembolism in Carriers and Non-carriers of the G1691A Allele in the Coagulation Factor V Gene and the G20210A Allele in the Prothrombin Gene , 1999, Thrombosis and Haemostasis.

[25]  M Gent,et al.  A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. , 1999, The New England journal of medicine.

[26]  L. Melton,et al.  Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. , 1999, Archives of internal medicine.

[27]  S. Schulman.  The effect of the duration of anticoagulation and other risk factors on the recurrence of venous thromboembolisms. Duration of Anticoagulation Study Group. , 1999, Wiener medizinische Wochenschrift.

[28]  J. Douketis,et al.  Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. , 1998, JAMA.

[29]  E. Minar,et al.  The Risk of Recurrent Venous Thromboembolism in Patients with and without Factor V Leiden , 1997, Thrombosis and Haemostasis.

[30]  Paolo Prandoni,et al.  The Long-Term Clinical Course of Acute Deep Venous Thrombosis , 1996, Annals of Internal Medicine.

[31]  P. Ridker,et al.  Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. , 1995, Circulation.

[32]  Olle Linder,et al.  A Comparison of Six Weeks with Six Months of Oral Anticoagulant Therapy after a First Episode of Venous Thromboembolism , 1995 .

[33]  K. Schulman,et al.  Cost-effectiveness analyses. , 1995, The New England journal of medicine.

[34]  D. Cooper,et al.  The molecular genetics of familial venous thrombosis. , 1991, Blood reviews.